^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MNPR 101

    i
    Other names: MNPR 101, ATN-658, huATN-658, Humanised ATN-658, MNPR-101, MNPR101
    Associations

    News

    Trials
    Company:
    Monopar Therap, Xoma
    Drug class:
    Urokinase-type plasminogen activator inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    MNPR101-Lu-1-01: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (clinicaltrials.gov)
    P1, N=12, Recruiting, Monopar Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MNPR 101
    2ms
    Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Monopar Therapeutics
    New P1 trial
    |
    MNPR 101
    almost4years
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma. (PubMed, Eur J Cancer)
    MNPR-101-IRDye800CW is suitable for multimodal imaging of UCC, awaiting clinical translation.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    |
    Rituxan (rituximab) • MNPR 101